The favorable indication from the pharma index is added positive for Biocon's stock
Biotechnology major Biocon on Monday said its subsidiary has joined hands with Libbs Farmaceutica to launch generic drugs in Brazil, the world's sixth most populous country.
RSI Indicator has given 'buy' signals on Biocon and VIP Industries' stocks
She further said, "Covid Vaccine Jab Capped At Rs 250 At Private Hospitals: Government - understand vaccine cos (sic) feel betrayed as price is too low to sustain"
IRFC has sold $750 million worth of dollar-denominated bonds to overseas investors priced at a coupon of just 2.80 per cent per annum
Biocon Biologics is an arm of biotechnology major Biocon
From its previous close of Rs 441.95 apiece on Thursday, the stock closed 10.89 per cent or Rs 48.15 lower at Rs 393.80, on Friday
Shares of Reliance Industries ended 2.4 per cent lower on Friday ahead of the announcement of its December quarter results. The shares have surged around 6 per cent during the week
Analysts have raised doubts over the $1 billion guidance for biosimilars by FY22 and Hamacher's exit due to "professional differences"
Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down as the MD of Biocon Biologics
SBI Cards and Payment Services reported nearly 52 per cent dip in its net profit to Rs 210 crore in the third quarter ended December 2020
Biocon's consolidated revenue for Q3 of FY21 increased by 7.20 per cent at Rs 1878.9 crore as against Rs 1752.6 crore for the said quarter last year
These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats
ADQ will invest Rs 555 Crore for a 1.80 per cent minority stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of around $4.17 billion
Biocon announced that its subsidiary Biocon Biologics has approved a primary equity investment by Abu Dhabi-based ADQ, one of the region's largest holding companies
Transaction values the IPO-bound biologics arm of Biocon at $3.94 billion
Launch of a cancer drug was delayed due to Covid-19
If Nifty again slide below 13,626, we may see some corrective move in the concluding week of the current calendar year
Biocon said its arm, Biocon Biologics, and Mylan have been informed by the USFDA of a deferred action on the biologics license application for a biosimilar to drug Avastin
India saw 37,975 new coronavirus infections in a day taking the country's Covid-19 caseload to 91.77 lakh